<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To describe a probable case of <z:hpo ids='HP_0010534'>transient global amnesia</z:hpo> caused by propafenone </plain></SENT>
<SENT sid="1" pm="."><plain>This adverse effect has not been previously described for this agent </plain></SENT>
<SENT sid="2" pm="."><plain>CASE SUMMARY: A 61-year old man with a history of <z:hpo ids='HP_0011704'>sick sinus syndrome</z:hpo> with persistent <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> and infrequent <z:hpo ids='HP_0006682'>premature ventricular contractions</z:hpo> was admitted to the hospital for symptoms of <z:e sem="disease" ids="C0002622" disease_type="Mental or Behavioral Dysfunction" abbrv="">amnesia</z:e> and <z:hpo ids='HP_0001289'>disorientation</z:hpo> to time, place, and date </plain></SENT>
<SENT sid="3" pm="."><plain>He began taking propafenone only 6 days prior to admission because of uncontrolled <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> and symptoms of <z:mp ids='MP_0002899'>fatigue</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>His <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> subsequently had converted to <z:mpath ids='MPATH_458'>normal</z:mpath> sinus rhythm while he received propafenone without adverse effects prior to this episode </plain></SENT>
<SENT sid="5" pm="."><plain>His symptoms of <z:e sem="disease" ids="C0002622" disease_type="Mental or Behavioral Dysfunction" abbrv="">amnesia</z:e> resolved approximately 6-7 hours after discontinuing the propafenone therapy </plain></SENT>
<SENT sid="6" pm="."><plain>DISCUSSION: Propafenone is a class 1C antiarrhythmic agent that blocks fast <z:chebi fb="199" ids="26708">sodium</z:chebi> channels in heart muscle and Purkinje fibers similar to the action of encainide and flecainide </plain></SENT>
<SENT sid="7" pm="."><plain>It also produces weak beta- and calcium-channel blockade </plain></SENT>
<SENT sid="8" pm="."><plain>It has a significant adverse effect profile, with 30-45% of patients reporting cardiac adverse effects and 15-20% experiencing noncardiac events </plain></SENT>
<SENT sid="9" pm="."><plain>Central <z:mp ids='MP_0008912'>nervous</z:mp> system effects that parallel <z:e sem="disease" ids="C0002622" disease_type="Mental or Behavioral Dysfunction" abbrv="">amnesia</z:e> have been reported in 10-15% of the patients, including dizziness, <z:hpo ids='HP_0001251'>ataxia</z:hpo>, <z:hpo ids='HP_0002329'>drowsiness</z:hpo>, <z:mp ids='MP_0002899'>fatigue</z:mp>, <z:hpo ids='HP_0001289'>confusion</z:hpo>, and <z:hpo ids='HP_0011999'>paranoia</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Propafenone's distribution, clearance, and structural similarity to <z:chebi fb="2" ids="8499">propranolol</z:chebi> contribute to its central <z:mp ids='MP_0008912'>nervous</z:mp> system effects </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: The rapid resolution of this patient's symptoms after discontinuing propafenone therapy and the absence of recurrence lend credence to the probability of this effect </plain></SENT>
<SENT sid="12" pm="."><plain>Comparable adverse effects, such as <z:hpo ids='HP_0001289'>disorientation</z:hpo> and <z:e sem="disease" ids="C0233796" disease_type="Mental or Behavioral Dysfunction" abbrv="">temporary amnesia</z:e>, have been reported in patients in the analogous agent, <z:chebi fb="2" ids="8499">propranolol</z:chebi> </plain></SENT>
<SENT sid="13" pm="."><plain>Consequently, this is a likely, although rare, possible adverse effect with propafenone for which patients should be monitored </plain></SENT>
</text></document>